The ARQL chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the ARQL chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The ARQL stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View ARQL Detailed Price Forecast - CNN Money||View ARQL Detailed Summary - Google Finance|
|View ARQL Detailed Summary - Yahoo! Finance||View ARQL Stock Research & Analysis - Zacks.com|
|View ARQL Trends & Analysis - Trade-Ideas||View ARQL Major Holders - Barrons|
|View ARQL Call Transcripts - NASDAQ||View ARQL Breaking News & Analysis - Seeking Alpha|
|View ARQL Annual Report - CompanySpotlight.com||View ARQL OTC Short Report - OTCShortReport.com|
|View ARQL Fundamentals - TradeKing||View ARQL SEC Filings - Bar Chart|
|View Historical Prices for ARQL - The WSJ||View Performance/Total Return for ARQL - Morningstar|
|View the Analyst Estimates for ARQL - MarketWatch||View the Earnings History for ARQL - CNBC|
|View the ARQL Earnings - StockMarketWatch||View ARQL Buy or Sell Recommendations - MacroAxis|
|View the ARQL Bullish Patterns - American Bulls||View ARQL Short Pain Metrics - ShortPainBot.com|
|View ARQL Stock Mentions - StockTwits||View ARQL Stock Mentions - PennyStockTweets|
|View ARQL Stock Mentions - Twitter||View ARQL Investment Forum News - Investor Hub|
|View ARQL Stock Mentions - Yahoo! Message Board||View ARQL Stock Mentions - Seeking Alpha|
|View Insider Transactions for ARQL - SECform4.com||View Insider Transactions for ARQL - Insider Cow|
|View ARQL Major Holdings Summary - CNBC||View Insider Disclosure for ARQL - OTC Markets|
|View Insider Transactions for ARQL - Yahoo! Finance||View Institutional Holdings for ARQL - NASDAQ|
|View ARQL Stock Insight & Charts - FinViz.com||View ARQL Investment Charts - StockCharts.com|
|View ARQL Stock Overview & Charts - BarChart||View ARQL User Generated Charts - Trading View|
ArQule Inc (NASDAQ:ARQL) Is Expected To Breakeven
Posted on Wednesday September 19, 2018
ArQule Inc’s (NASDAQ:ARQL): ArQule, Inc., a biopharmaceutical company, researches and develops therapeutics for the treatment of cancer and rare diseases in the United States. The US$548.4m market-cap company’s loss lessensRead More...
Miransertib (ARQ 092) Granted Fast Track Designation for the Treatment of PIK3CA-Related Overgrowth Spectrum (PROS)
Posted on Thursday September 13, 2018
ArQule, Inc. (ARQL) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to miransertib (ARQ 092) for the treatment of PIK3CA-Related Overgrowth Spectrum (PROS), a group of related, ultra-rare genetic disorders characterized by excessive tissue growth in various parts of the body. The FDA’s Fast Track program aims to expedite the development and review of drugs which treat serious or life-threatening conditions and have demonstrated the potential to address unmet clinical needs. Miransertib has already been granted Rare Pediatric Disease Designation by the FDA and Orphan Designation by the FDA and European Medicines Agency in the rare overgrowth disease, Proteus syndrome.
Implied Volatility Surging for ArQule (ARQL) Stock Options
Posted on Wednesday September 05, 2018
Investors need to pay close attention to ArQule (ARQL) stock based on the movements in the options market lately.
ArQule to Participate in the Annual B. Riley FBR Healthcare Conference on September 4, 2018
Posted on Thursday August 30, 2018
ArQule, Inc. today announced that Paolo Pucci, CEO, and Dr. Brian Schwartz, CMO and Head of Research and Development, will participate in investor meetings and scientific panel discussions at the B.